Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Angiotensin 1-7 Clear all
Withdrawn Phase 2 Interventional

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

NCT01554254
View directory record Official record
Conditions
Cord Blood Transplant, Hematologic Malignancy, Inherited Metabolic Disease
Interventions
TXA127
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
6 Months to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Sep 28, 2026, 6:45 PM EDT
Recruiting Phase 2 Interventional

A Study of Blood Pressure Control During Cancer Treatment

NCT06023576
View directory record Official record
Conditions
Breast Cancer, Cardiotoxicity
Interventions
antihypertensive medications, Blood pressure measurement, Echocardiogram, Symptom-limited cardiopulmonary exercise test, Quality of Life Measures, Biomarkers
Other · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 28, 2026, 6:45 PM EDT
Terminated Early Phase 1 Interventional

Angiotensin-(1-7) in Peripheral Arterial Disease

NCT03240068
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Angiotensin 1-7, Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 28, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

TXA127 for the Treatment of Severe COVID-19

NCT04401423
View directory record Official record
Conditions
COVID-19
Interventions
TXA127, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 28, 2026, 6:45 PM EDT
Not listed Phase 1Phase 2 Interventional

Biomarker Study: Heart Failure Patients at Risk

NCT05336175
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
Angiotensin 1-7, Saline solution
Drug
Lead sponsor
University of Arizona
Other
Eligibility
45 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 28, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

NCT00771810
View directory record Official record
Conditions
Thrombocytopenia, Neutropenia, Lymphopenia, Anemia
Interventions
TXA127, Placebo
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 28, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00471562
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
therapeutic angiotensin-(1-7)
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 28, 2026, 6:45 PM EDT
Terminated Phase 1 Interventional

TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation

NCT01300611
View directory record Official record
Conditions
Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Myelofibrosis, Acute Lymphoblastic Leukemia, Chronic Myelocytic Leukemia, Non Hodgkins Lymphoma, Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
TXA127 300 mcg/kg/day, TXA127 1000 mcg/kg/day
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 28, 2026, 6:45 PM EDT
Terminated Phase 2 Interventional

Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients

NCT01121120
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Hodgkin Disease, Multiple Myeloma
Interventions
TXA127, Placebo
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
10
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 28, 2026, 6:45 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans

NCT02386293
View directory record Official record
Conditions
Hypertension, Obesity, Stress, Psychological, Blood Pressure
Interventions
Irbesartan, Placebo
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Sep 28, 2026, 6:45 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress

NCT02432339
View directory record Official record
Conditions
Psychological Stress, Hypertension, Renal
Interventions
mycophenolate mofetil (MMF), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Sep 28, 2026, 6:45 PM EDT
Terminated Phase 4 Interventional Results available

Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

NCT02788656
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Implantable Hemodynamic Monitor, Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Type 1 Receptor Blocker, sacubitril/valsartan
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 28, 2026, 6:45 PM EDT
Terminated Early Phase 1 Interventional

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

NCT02591173
View directory record Official record
Conditions
Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 28, 2026, 6:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

NCT03310684
View directory record Official record
Conditions
Pediatric Disorder, Pediatric Obesity, Primary Hypertension
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
5 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 28, 2026, 6:45 PM EDT
Recruiting Phase 4 Interventional

The STOP-MED CTRCD Trial

NCT06183437
View directory record Official record
Conditions
Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Interventions
Stopping Heart Failure Medication(s)
Other
Lead sponsor
Dinesh Thavendiranathan
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 28, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

NCT01281306
View directory record Official record
Conditions
Systolic Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 28, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs)

NCT01543971
View directory record Official record
Conditions
Miscellaneous Peripheral Blood Cell Abnormalities
Interventions
TXA127, Neupogen (filgrastim)
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Sep 28, 2026, 6:45 PM EDT
Suspended Phase 2 Interventional

Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients

NCT03159988
View directory record Official record
Conditions
Chronic Heart Failure, Cognitive Impairment
Interventions
Angiotensin-(1-7), Memory Training
Drug · Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
55 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 28, 2026, 6:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Local Vasoconstriction in Postural Tachycardia Syndrome

NCT01210430
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Losartan, Ascorbic Acid (Vitamin C), Normal Saline
Drug
Lead sponsor
New York Medical College
Other
Eligibility
14 Years to 29 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 28, 2026, 6:45 PM EDT
Completed Early Phase 1 Interventional

Angiotensin-(1-7) and Energy Expenditure in Human Obesity

NCT03777215
View directory record Official record
Conditions
Obesity
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Amy Arnold
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 6:45 PM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

NCT01882387
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
TXA127
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Atlanta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Sep 28, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 28, 2026, 6:45 PM EDT